Opportunity Information: Apply for CK14 1401PPHFSUPP15
Apply for CK14 1401PPHFSUPP15
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "Domestic Ebola Supplement to Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) Building and Strengthening Epidemiology, Laboratory and Health Information Systems Capacity in State and Local Health Departments" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.323 Epidemiology and Laboratory Capacity for Infectious Diseases (ELC).
- This funding opportunity was created on Jan 21, 2015 and posted on Jan 20, 2015.
- Applicants must submit their applications by Feb 19, 2015 Electronically submitted applications must be submitted no later than 1159 p.m., ET, on the listed application due date.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $106,000,000.00 to eligible and selected applicants.
- The number of recipients for this funding is limited to 64 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification) County governments City or township governments State governments.
- Eligibility for these supplemental funds is limited to current ELC grantees (previously funded under CK14 1401PPHF2014).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Domestic Ebola Supplement to the Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) program was a CDC discretionary funding opportunity designed to quickly strengthen the ability of state, territorial, and local health departments to prevent, prepare for, and respond to Ebola and other emerging infectious diseases. Structured as a cooperative agreement, it emphasized active partnership between CDC and awardees, with funding intended to expand practical, on-the-ground public health capabilities rather than support a one-time, isolated project.
The supplemental announcement focused on three main areas of work. First, it supported infection prevention and control activities, which generally means improving readiness in healthcare and public health settings to identify potential cases, protect healthcare workers and the public, and implement safe clinical and public health practices that reduce the risk of transmission. Second, it supported laboratory capacity for biosafety, aiming to ensure public health laboratories have the procedures, training, and safety infrastructure needed to manage and test high-consequence pathogens appropriately, including safe specimen handling and strengthened biosafety practices. Third, it supported screening related to global migration at domestic ports of entry, reflecting the need for stronger coordination and capacity to assess and manage potential risks associated with international travel and arrival screening, especially during periods of heightened concern about imported cases.
Funding for this supplement was substantial, with an estimated total of $106,000,000 and an expected 64 awards. There was no cost sharing or matching requirement. The opportunity was tied to the existing ELC framework (CFDA 93.323), meaning it was designed to build on the nationwide disease surveillance, epidemiology, and laboratory systems that ELC typically supports, and to accelerate Ebola-specific and broader emerging infectious disease readiness through those established channels. While the award ceiling and floor were listed as zero, that typically indicates variable award sizes determined by CDC based on programmatic needs, jurisdictional risk, and planned activities rather than a fixed minimum or maximum amount per recipient in the public synopsis.
Eligibility was limited: only current ELC grantees funded under the prior ELC announcement (CK14 1401PPHF2014) could apply for these supplemental funds. Eligible applicant types included state governments, county governments, and city or township governments, but the key constraint was being an existing ELC awardee. This limitation reflects the practical goal of moving funds quickly to organizations already operating ELC-supported systems, with established agreements, staffing structures, and reporting mechanisms, so expanded Ebola and emerging infectious disease activities could be implemented without the delays that often come with onboarding brand-new recipients.
The opportunity was posted on January 20, 2015, created on January 21, 2015, and had an application deadline of February 19, 2015, with electronic submissions due by 11:59 p.m. Eastern Time on the closing date. The archive date was March 23, 2015. The sponsoring agency was the Centers for Disease Control and Prevention, and applicants needing help accessing the full announcement were directed to contact CDC’s procurement/grants office via PGOTIM@cdc.gov. Additional program information was referenced through a CDC link associated with the ELC program.
In practical terms, this supplement was meant to push additional resources into jurisdictions already responsible for core public health surveillance and laboratory work, so they could enhance preparedness and response functions during the Ebola period while also leaving behind stronger systems relevant to future outbreaks. The three activity areas signal an approach that connects healthcare infection control, public health laboratory safety and capability, and traveler/arrival screening operations into one coordinated readiness effort, which is often essential when managing high-impact infectious disease threats that can enter through travel and require rapid identification, safe testing, and effective containment.
Frequently Asked Questions (FAQs)
1) What is the Domestic Ebola Supplement to the ELC program?
It was a CDC discretionary funding opportunity that provided supplemental funding under the Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) program to quickly strengthen state, territorial, and local health departments' ability to prevent, prepare for, and respond to Ebola and other emerging infectious diseases.
2) Which agency sponsored this funding opportunity?
The sponsoring agency was the Centers for Disease Control and Prevention (CDC).
3) What type of grant mechanism was used?
The supplement was structured as a cooperative agreement, meaning it emphasized an active partnership between CDC and the awardees rather than a hands-off, one-time project grant approach.
4) What was the main purpose of the supplement?
The main purpose was to expand practical, on-the-ground public health capabilities for Ebola readiness and response, while also strengthening broader systems relevant to other emerging infectious disease threats.
5) What were the main areas of work supported by the supplement?
The announcement focused on three areas: (1) infection prevention and control activities, (2) laboratory capacity for biosafety, and (3) screening related to global migration at domestic ports of entry.
6) What does "infection prevention and control" mean in this context?
In this supplement, infection prevention and control generally referred to improving readiness in healthcare and public health settings to identify potential cases, protect healthcare workers and the public, and implement safe clinical and public health practices that reduce transmission risk.
7) What does "laboratory capacity for biosafety" cover?
It aimed to ensure public health laboratories had appropriate procedures, training, and safety infrastructure to manage and test high-consequence pathogens. This included safe specimen handling and strengthened biosafety practices.
8) What is meant by screening related to global migration at domestic ports of entry?
It referred to strengthening coordination and capacity to assess and manage risks associated with international travel and arrival screening at U.S. ports of entry, especially during periods of heightened concern about imported cases.
9) How much total funding was expected to be available?
The estimated total funding was $106,000,000.
10) How many awards were expected?
CDC expected to make 64 awards.
11) Was there a cost sharing or matching requirement?
No. The opportunity stated there was no cost sharing or matching requirement.
12) What was the CFDA number associated with this opportunity?
The supplement was tied to the ELC framework under CFDA 93.323.
13) What does it mean that the supplement was tied to the existing ELC framework?
It means the supplemental funds were designed to build on ELC-supported nationwide disease surveillance, epidemiology, and laboratory systems, using established channels to accelerate Ebola-specific and broader emerging infectious disease readiness.
14) Who was eligible to apply?
Eligibility was limited to current ELC grantees funded under the prior ELC announcement CK14 1401PPHF2014. In other words, applicants had to already be ELC awardees under that specific prior announcement to apply for the supplemental funds.
15) What applicant organizations were included as eligible types?
Eligible applicant types included state governments, county governments, and city or township governments, with the key eligibility requirement being current ELC grantee status under the specified prior ELC announcement.
16) Why was eligibility limited to existing ELC awardees?
The limitation was intended to move funds quickly to organizations already operating ELC-supported systems and already set up with agreements, staffing structures, and reporting mechanisms, reducing delays that can occur when onboarding new recipients.
17) What were the key dates for the opportunity?
The opportunity was posted on January 20, 2015, created on January 21, 2015, and the application deadline was February 19, 2015.
18) What time were applications due on the deadline date?
Electronic submissions were due by 11:59 p.m. Eastern Time on the closing date.
19) What was the archive date?
The archive date was March 23, 2015.
20) Were award amounts fixed per recipient?
The public synopsis listed the award ceiling and floor as zero, which typically indicates award sizes were variable and determined by CDC based on programmatic needs, jurisdictional risk, and planned activities rather than a fixed minimum or maximum amount per recipient.
21) What kind of outcomes was CDC aiming for with this supplement?
The supplement was intended to enhance preparedness and response functions during the Ebola period and leave behind strengthened systems useful for future outbreaks, connecting healthcare infection control, public health laboratory safety/capability, and traveler/arrival screening operations into a coordinated readiness approach.
22) Where could applicants get help accessing the full announcement?
Applicants needing help accessing the full announcement were directed to contact CDC's procurement/grants office at PGOTIM@cdc.gov.
23) Was additional program information referenced for this opportunity?
Yes. Additional program information was referenced through a CDC link associated with the ELC program.
Browse more opportunities from the same agency: Centers for Disease Control and Prevention
Browse more opportunities from the same category: Health
Next opportunity: Service Area Competition Additional Areas (SAC AA) GA KS LA MS MT PA SC TX and WA
Previous opportunity: State Energy Program 2015 Competitive Awards
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CK14 1401PPHFSUPP15
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (CK14 1401PPHFSUPP15) also looked into and applied for these:
| Funding Opportunity |
|---|
| Service Area Competition Additional Areas (SAC AA) GA KS LA MS MT PA SC TX and WA Apply for HRSA 15 141 Funding Number: HRSA 15 141 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Rural Health Value Program Apply for HRSA 15 072 Funding Number: HRSA 15 072 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Maternal and Child Health (MCH) Interdisciplinary Education in Pediatric Pulmonary Centers (PPCs) Apply for HRSA 15 074 Funding Number: HRSA 15 074 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Metabolomics Core for the Undiagnosed Diseases Network (UDN) (U01) Apply for RFA RM 15 001 Funding Number: RFA RM 15 001 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| FY15 Announcement of the Anticipated Availability of Funds for Phase I Research on Research Integrity Apply for IR ORI 15 001 Funding Number: IR ORI 15 001 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $75,000 |
| Natural Experiments of the Impact of Population targeted Health Policies to Prevent Diabetes and its Apply for RFA DP 15 001 Funding Number: RFA DP 15 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Well Integrated Screening and Evaluation for Women Across the Nation (WISEWOMAN) Program Apply for CDC RFA DP13 130203CONT15 Funding Number: CDC RFA DP13 130203CONT15 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Enhancing HIV Prevention Communication and Mobilization Efforts through Strategic Partnerships Apply for CDC RFA PS15 1505 Funding Number: CDC RFA PS15 1505 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $150,000 |
| EMS for Children Pediatric Emergency Care Applied Research Network (PECARN) Apply for HRSA 15 066 Funding Number: HRSA 15 066 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Strengthening and Enhancing National HIV/AIDS Prevention, Diagnosis, Care,Treatment, Monitoring Surveillance of Communicable Non communicable Diseases with the MOH in the Republic of Haiti under PEPFAR,Public Health Social Services Emergency Fund Apply for CDC RFA GH15 1527 Funding Number: CDC RFA GH15 1527 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000,000 |
| Screening, Brief Intervention, and Referral to Treatment (SBIRT) Health Professions Student Training (SBIRT Student Training) Apply for TI 15 001 Funding Number: TI 15 001 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $315,000 |
| Research to Evaluate the CDC Heads Up Concussion Initiative in Youth Sports Apply for RFA CE 15 005 Funding Number: RFA CE 15 005 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $550,000 |
| Grants to Expand Substance Abuse Treatment Capacity in Adult and Family Drug Courts (SAMHSA Treatment Drug Courts) Apply for TI 15 002 Funding Number: TI 15 002 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $325,000 |
| Institutional Training for a Dental, Oral and Craniofacial Research Workforce (T90/R90) Apply for PAR 15 101 Funding Number: PAR 15 101 Agency: National Institutes of Health Category: Health Funding Amount: $550,000 |
| Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Training for a Dental, Oral and Craniofacial Research Workforce (T32) Apply for PAR 15 102 Funding Number: PAR 15 102 Agency: National Institutes of Health Category: Health Funding Amount: $550,000 |
| Maximizing Investigators Research Award (R35) Apply for RFA GM 16 002 Funding Number: RFA GM 16 002 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Exploratory Technologies to Understand the Control of Organ Function by the Peripheral Nervous System for SPARC (U18) Apply for RFA RM 15 002 Funding Number: RFA RM 15 002 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| NIAMS Musculoskeletal Biology and Medicine Resource based Centers (P30) Apply for RFA AR 16 004 Funding Number: RFA AR 16 004 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Systems Biology and Antibacterial Resistance (U01) Apply for RFA AI 14 064 Funding Number: RFA AI 14 064 Agency: National Institutes of Health Category: Health Funding Amount: $2,000,000 |
| Maternal and Child Health Public Health Catalyst Program Apply for HRSA 15 133 Funding Number: HRSA 15 133 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CK14 1401PPHFSUPP15", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.